Trials / Completed
CompletedNCT05759273
A Study to Observe Demography and the Outcome of Prostate Cancer Patients Treated With 6-month Triptorelin Formulation in Italy
Retrospective, Noninterventional Study Assessing the Real-Life Use of The Long-Acting 6-Month Triptorelin Formulation as A Treatment for Different Stages of Prostate Cancer in Italy - REAL6T
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 167 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The participants of this study had Prostate Cancer. Prostate cancer is cancer that occurs in the prostate, a small gland in the male reproductive system. This study will collect data on the use of the 6-month triptorelin formulation (Decapeptyl®) in local routine clinical practice as a treatment for different stages of prostate cancer. The aim of this study will be to describe participant characteristics, as well as disease and treatment characteristics before the first injection with the 6-month triptorelin formulation in Italy. The decision to prescribe this product and all hospital visits, dose adjustments, assessments and procedures were made according to routine clinical practice at the time and independently of the decision to enroll the participants in this data collection study.
Conditions
Timeline
- Start date
- 2023-04-24
- Primary completion
- 2024-09-30
- Completion
- 2024-09-30
- First posted
- 2023-03-08
- Last updated
- 2024-11-01
Locations
13 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT05759273. Inclusion in this directory is not an endorsement.